Recently, Illumina Inc. (ILMN) expanded its suite of TruSight content sets by adding TruSight Tumor to its portfolio. TruSight’s content set is created according to different diseases. Inherited disease, exome, cardiomyopathy, cancer and autism form an important part of TruSight’s content set.
This new product is capable of detecting different types of tumors in the body including melanoma, colon, lung, ovary and gastric cancer. This product will enable somatic variant detection in solid tumors by running on Illumina’s popular MiSeq platform.
TruSight Tumor, in an economic way, provides exhaustive solutions on tumor heterogeneity in comparison with the gene-based methods. The researchers can also identify physical changes in multiple genes across the tumor genome.
Explaining the heterogeneity approach, the company said that TruSight Tumor is equipped with technology that would not miss a single candidate for targeted therapy, which could have been missed under single gene approach. With restricted DNA input, TruSight Tumor has the capability for allele detection.
Illumina is due to report its first quarter 2013 results on Apr. 22, 2013. The Zacks Consensus Estimate of EPS for the quarter stands at $0.38. ILMN has beaten the Zacks Consensus earnings estimate in three out of past four quarters. Currently, Illumina carries a Zacks Rank #4 (Sell). This California-based company develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function on a broader scale.
Additionally, Illumina provides medium for further development in consumer genomics and diagnostics. The company’s products and technology transforms healthcare through advanced genetic analysis research and its application.Read the Full Research Report on ILMN
More From Zacks.com
- Biotechnology Science
- Science, Social Science, & Humanities